A total of 4%, 8% and 11% of patients discontinued therapy due to intolerance in the placebo, DEPAKOTE, and lithium carbonate groups, respectively. The cause of the increased sensitivity to the anticoagulant effects of neurontin in this age group is unknown. Similar outcomes have been reported with COZAAR. This means that NEURONTIN can be a target for people who abuse prescription medicines. PREVACID® is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer. Pooled data from four clinical studies indicate that 40% of all patients treated with 120 mg three times a day of NEURONTIN and 24% of patients treated with placebo who completed 2 years of the same therapy had ? 5% loss of body weight from randomization. Body as a Whole-general disorders: Asthenia, Fever, Hernia. At the end of the study, the mean percent weight loss in the placebo group was -2.75% compared with -5.17% in the neurontin drug group (p 0.001) (see Figure 1). Do not prescribe ULTRAM® for patients who are suicidal or addiction-prone. if you are allergic to alprazolam or to other benzodiazepines, such as chlordiazepoxide (Librium), clorazepate (Tranxene), neurontin drug (Valium), lorazepam (Ativan), or oxazepam (Serax). Before having surgery, tell your doctor or dentist that you are taking this medication. The efficacy and safety of NEURONTIN DRUG for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established.